These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38040664)

  • 1. Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong.
    Cheung YYH; Lau EHY; Yin G; Lin Y; Cowling BJ; Lam KF
    Emerg Infect Dis; 2024 Jan; 30(1):70-78. PubMed ID: 38040664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach.
    Cheung YYH; Lau EHY; Yin G; Lin Y; Jiang J; Cowling BJ; Lam KF
    Int J Infect Dis; 2024 Jun; 143():107012. PubMed ID: 38521448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.
    Wang H; Wei Y; Hung CT; Lin G; Jiang X; Li C; Jia KM; Yam CHK; Chow TY; Ho JY; Wang Y; Zhao S; Guo Z; Li K; Yang A; Mok CKP; Hui DSC; Yeoh EK; Chong KC
    Lancet Infect Dis; 2024 Oct; 24(10):1130-1140. PubMed ID: 38710190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
    McMenamin ME; Nealon J; Lin Y; Wong JY; Cheung JK; Lau EHY; Wu P; Leung GM; Cowling BJ
    Lancet Infect Dis; 2022 Oct; 22(10):1435-1443. PubMed ID: 35850128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
    Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
    PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
    Smith DJ; Hakim AJ; Leung GM; Xu W; Schluter WW; Novak RT; Marston B; Hersh BS
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(15):545-548. PubMed ID: 35421076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of CoronaVac and BNT162b2 Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.2 Infections in Hong Kong.
    Yang B; Wong IOL; Xiao J; Tsang TK; Liao Q; Cowling BJ
    J Infect Dis; 2022 Oct; 226(8):1382-1384. PubMed ID: 36054016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
    Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
    Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study.
    Yan VKC; Cheng FWT; Chui CSL; Lai FTT; Wong CKH; Li X; Wan EYF; Wong JSC; Chan EWY; Wong ICK; Kwan MYW; Ip P
    Emerg Microbes Infect; 2023 Dec; 12(1):2185455. PubMed ID: 36852582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study.
    Lai FTT; Wang B; Wei C; Chui CSL; Li X; Cheung CL; Wong ICK; Chan EWY; Wan EYF
    Age Ageing; 2024 Aug; 53(8):. PubMed ID: 39141078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.